Amgen price target raised to $315 from $305 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on Amgen (AMGN) to $315 from $305 and keeps a Neutral rating on the shares. Amgen reported a straightforward Q3 beat, justifying higher guidance, the analyst tells investors in a research note. The confirmation of a delay of olpasiran OCEAN data into 2027 likely puts even more focus on commercial dynamics over at least the first half of 2026, the firm says.